MapLight Therapeutics

News

MapLight Therapeutics has made its debut on the Nasdaq, raising $251m for a lead drug that could be a rival to BMS' new schizophrenia drug Cobenfy.

Oncology

Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.